The phase 1 clinical trial of the oral insulin drug from the Banglore-based Biocon Limited, will be commenced within a month.

The company recently received the approval from the authorities and the trials will be carried out with the help of the Karolinska Institute, Sweden. The company is expecting a good result, which can bring a change in the field of diabetes treatment, according to Dr. Kiran Mazumdar Shaw.

Biocon is entering the new financial year with plans for more product launches. The company will launch an oncology product very soon, this year. There are plans to expand its market to Middle East.

"Biocon has already invested heavily in research and development. We expect to come up with some exciting products in this year," said Mazumdar. She was here to attend an Indo-Swedish Symposium on Genomics and Proteomics of Diabetes, organized by Madras Diabetes Research Institute (MDRF).

The company has completed clinical trials on an antibody for treating cancer, with good results. The cancer drug is also expected to hit the market soon, she said.